Jul 02, 2019 / 12:30PM GMT
Operator
Hello, ladies and gentlemen, thank you for standing by and welcome to Zai Lab's Conference Call to discuss its development and exclusive commercial collaboration and license agreement with Incyte. (Operator Instructions).
As a reminder, today's call is being recorded. It is now my pleasure to turn the call over to Billy Cho, Chief Financial Officer of Zai Lab, who will make introductory comments. Please go ahead, sir.
Ki Chul Cho - Zai Lab Limited - CFO
Thank you, operator. Good morning, everyone, and welcome to Zai Lab's Conference Call to discuss our development and exclusive commercial collaboration and license agreement for INCMGA0012, an investigational anti-PD-1 monoclonal antibody with Incyte. Earlier today, Zai Lab and Incyte issued a release providing the details of agreement. The press release is available in the IR section of the company's corporate website at ir.zailaboratory.com.
Joining me on this call will be Dr. Samantha Du, Zai Lab's Chairman and Chief Executive Officer; Tao Fu, President and COO; Jonathan Wang, Head of BD;
Zai Lab Ltd and Incyte Corp to Discuss the Collaboration and License Agreement for INCMGA0012 in Greater China Call Transcript
Jul 02, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers